- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
More ▼
Key statistics
On Friday, Axsome Therapeutics Inc (19X:DUS) closed at 78.60, -13.23% below its 52-week high of 90.58, set on Feb 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 78.78 |
---|---|
High | 78.92 |
Low | 78.44 |
Bid | 78.80 |
Offer | 80.14 |
Previous close | 79.02 |
Average volume | 42.50 |
---|---|
Shares outstanding | 47.50m |
Free float | 38.30m |
P/E (TTM) | -- |
Market cap | 4.11bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 18:30 BST.
More ▼